GLP-1 Drugs Reduce Depression, Boost Stress-Calming Gut Bacteria
Researchers at Southeast University found that GLP-1 receptor agonist drugs like liraglutide reduce depression in mice by accumulating in the gut, not the brain, and boosting the *Lactobacillus delbrueckii* bacteria, which produces a precursor for the stress-calming endocannabinoid 2-AG. The study, published in *Cell Host & Microbe*, challenges the brain-centric model of these drugs’ antidepressant effects and suggests gut microbiome manipulation could offer new depression treatment pathways." "article": "A study published in *Cell Host & Microbe* on June 10 reveals that GLP-1 receptor agonist drugs, such as liraglutide—commonly prescribed for diabetes and obesity—may alleviate depression through gut bacteria rather than direct brain action. Researchers at Southeast University in China used mouse models to demonstrate that liraglutide primarily accumulates in the intestine, where it triggers a surge in *Lactobacillus delbrueckii*, a gut microbe linked to stress regulation. The findings contradict prior assumptions that these drugs act on neural receptors in the brain. Genetically modified mice lacking GLP-1 receptors still showed antidepressant effects from liraglutide, confirming the gut’s role. When antibiotics wiped out the mice’s gut microbiomes, the drug’s mood benefits disappeared, proving its reliance on living microbes. Fecal sequencing identified *L. delbrueckii* as the dominant microbial strain after liraglutide treatment, correlating directly with behavioral improvements. The bacteria produce diacylglycerol, a precursor converted by the body into 2-arachidonoylglycerol (2-AG), an endocannabinoid that calms hyperactive stress-related brain regions. The discovery suggests targeted probiotics could treat depression in patients with obesity or type 2 diabetes. However, the study’s use of male mice limits conclusions about female subjects, emphasizing the need for further research. Lead author Yonggui Yuan noted that prior clinical studies on GLP-1 drugs yielded mixed results, with some showing antidepressant effects and others indicating mood risks. This study resolves the contradiction by pinpointing the gut microbiome as the critical mediator.
A study published in *Cell Host & Microbe* on June 10 reveals that GLP-1 receptor agonist drugs, such as liraglutide—commonly prescribed for diabetes and obesity—may alleviate depression through gut bacteria rather than direct brain action. Researchers at Southeast University in China used mouse models to demonstrate that liraglutide primarily accumulates in the intestine, where it triggers a surge in *Lactobacillus delbrueckii*, a gut microbe linked to stress regulation. The findings contradict prior assumptions that these drugs act on neural receptors in the brain. Genetically modified mice lacking GLP-1 receptors still showed antidepressant effects from liraglutide, confirming the gut’s role. When antibiotics wiped out the mice’s gut microbiomes, the drug’s mood benefits disappeared, proving its reliance on living microbes. Fecal sequencing identified *L. delbrueckii* as the dominant microbial strain after liraglutide treatment, correlating directly with behavioral improvements. The bacteria produce diacylglycerol, a precursor converted by the body into 2-arachidonoylglycerol (2-AG), an endocannabinoid that calms hyperactive stress-related brain regions. The discovery suggests targeted probiotics could treat depression in patients with obesity or type 2 diabetes. However, the study’s use of male mice limits conclusions about female subjects, emphasizing the need for further research. Lead author Yonggui Yuan noted that prior clinical studies on GLP-1 drugs yielded mixed results, with some showing antidepressant effects and others indicating mood risks. This study resolves the contradiction by pinpointing the gut microbiome as the critical mediator.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.